Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 18, Issue 9, Pages 837-860Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2018.1496822
Keywords
Neuroendocrine tumor; imaging; MRI; CT scan; somatostatin receptor imaging; gastrinoma; insulinoma; MEN1
Categories
Funding
- intramural program of National Institutes of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [NIDDK] [DK053200-26]
Ask authors/readers for more resources
Introduction: Recently, there have been a number of advances in imaging pancreatic neuroendocrine tumors (panNETs), as well as other neuroendocrine tumors (NETs), which have had a profound effect on the management and treatment of these patients, but in some cases are also associated with controversies.Areas covered: These advances are the result of numerous studies attempting to better define the roles of both cross-sectional imaging, endoscopic ultrasound, with or without fine-needle aspiration, and molecular imaging in both sporadic and inherited panNET syndromes; the increased attempt to develop imaging parameters that correlate with tumor classification or have prognostic value; the rapidly increasing use of molecular imaging in these tumors and the attempt to develop imaging parameters that correlate with treatment/outcome results. Each of these areas and the associated controversies are reviewed.Expert commentary: There have been numerous advances in all aspects of the imaging of panNETs, as well as other NETs, in the last few years. The advances are leading to expanded roles of imaging in the management of these patients and the results being seen in panNETs/GI-NETs with these newer techniques are already being used in more common tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available